After a market crushing performance during the first half of the year, one of 2020’s best performers has been struggling of late. The last month has seen shares of Inovio Pharmaceuticals (INO) decline by 27%. The publication of murky data for the biotech’s COVID-19 DNA vaccine candidate INO-4800 and a sense it is lagging behind competitors’ progress have raised concerns amongst investors. Add in an overheated valuation and maybe a sell off was inevitable.As a reminder, despite the souring sentiment, the stock is still up by a majestic 510% on a year-to-date basis.With the public and investors’ …read more
Source:: Yahoo Finance
